Both organ transplantation and umbilical cord blood transplantation can use HLA genotyping to achieve recipient donor matching. The higher the HLA compatibility between recipients and donors, the lower the incidence of rejection, and the higher the success rate of transplantation, long-term survival rate of transplanted organs, and the effectiveness of umbilical cord blood transplantation

Hematopoietic stem cell transplantation, which requires higher transplantation requirements, is currently the most fundamental treatment option for various malignant blood diseases. Accurate HLA typing combined with gene sequencing and matching can reduce graft-versus-host response (GVHD) and improve the success rate of transplantation. At present, clinical testing mainly uses PCR based methods for initial screening, sequencing for review and selection of the best. Methods that can achieve absolute high typing of HLA include Sanger sequencing based typing (SBT) and second-generation sequencing technology (NGS). Weihe Biotechnology can provide a series of testing solutions covering pre transplantation, during transplantation, and post transplantation.